Dupixent Has Been Linked to Several Types of T-cell Lymphoma
In a rush? You can use our Quick Contact Form to tell us the basic information about your case.
Dupixent-related cancers that involve the skin include:
- T-cell lymphoma
- Cutaneous T-cell lymphoma (CTCL)
- Peripheral T-cell lymphoma (PTCL)
- Mycosis fungoides
- Sézary syndrome
We are currently investigating possible Dupixent drug injury lawsuits for patients who were diagnosed with one of those Dupixent-related cancers after they started using Dupixent (dupilumab). These Dupixent lawsuits would be filed against the pharmaceutical companies Regeneron Pharmaceuticals, Inc., and Sanofi-Aventis U.S. LLC.
Here are the two primary reasons why:
- An April 2024 medical article, “Dupilumab treatment for atopic dermatitis linked to cutaneous T-cell lymphoma development“, presented some findings from a recent study that showed patients using Dupixent for treatment of their atopic dermatitis had an increased risk for cutaneous T-cell lymphoma (CTCL). It started with this “Key takeaways” fact: “[Dupixent (dupilumab)]-treated patients with AD were 4.1003 times more likely to develop cutaneous T-cell lymphoma vs. those who were not [Dupixent (dupilumab)]-treated.” [Emphasis added]
- Significantly, the U.S. Prescribing Information document, or “drug label”, for Dupixent (accessed 10/6/25) [PDF, 71 pages] does not have any warning about an association between Dupixent and the development or exacerbation of T-cell lymphoma.
Medical Information About Dupixent-related Cancers
Here is some background information about Dupixent-related cancers.
We start with T-cell lymphoma explanatory information:
- There are several types of T-cell lymphoma, including cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL).
- CTCL is a T-cell lymphoma that starts in the skin, whereas PTCL refers to systemic T-cell lymphomas that are found in the lymph nodes, other organs, and the blood. Also, some types involve the skin.
- Mycosis fungoides and Sézary syndrome are the two most common subtypes of CTCL.
This medical information about cutaneous T-cell lymphoma (CTCL) comes from the Cutaneous Lymphoma Foundation website:
Cutaneous T-cell lymphoma (CTCL) is the most common type of cutaneous lymphoma, and typically presents with red, scaly patches or plaques on the skin. Itching is common, with more than 80% of people with CTCL reporting they have itch. CTCL often mimics eczema, psoriasis, or other chronic dermatitis, and because of this it’s common that the diagnosis of CTCL is delayed, sometimes by years or decades….
From their Mycosis Fungoides page:
Mycosis fungoides (MF) is the most common form of cutaneous T-cell lymphoma (CTCL). Although the terms MF and CTCL are often used interchangeably, this can be a source of confusion. All cases of MF are CTCL, but not all CTCL cases are MF.
Mycosis fungoides follows a slow, chronic (indolent) course and very often does not spread beyond the skin.
And from their Sézary Syndrome page:
Sézary syndrome is a leukemic form of CTCL, and distinguished from mycosis fungoides by the presence of cancerous lymphocytes in the blood…
Although Sézary syndrome can affect people of any age, Sézary syndrome is most common in adults ages 50 and over, and is slightly more common in men than women.
This medical information about peripheral T-cell lymphoma (PTCL) comes from the Lymphoma Research Foundation:
Peripheral T-cell lymphoma (PTCL) is defined as a diverse group of aggressive lymphomas that develop from mature-stage white blood cells called T-cells and natural killer (NK) cells.
PTCL is classified as a subtype of non-Hodgkin lymphoma (NHL). NHL affects two particular types of white blood cells: B-cells and T-cells. PTCL specifically affects T-cells, and results when T-cells develop and grow abnormally.
It is PTCL’s origin in the lymphatic system that gave it the name peripheral T-cell lymphoma. In the case of PTCL, the term “peripheral” does not refer to the extremities, but identifies PTCL as a cancer that arises in the lymphoid tissues outside of the bone marrow such as lymph nodes, spleen, gastrointestinal tract, and skin.
Finally, returning to the April 2024 medical article pointed out (#1) in the introductory section above, the complete findings from that Dupixent – CTCL study were reported in this medical journal article, “Dupilumab therapy for atopic dermatitis is associated with increased risk of cutaneous T cell lymphoma: A retrospective cohort study“, published by the Journal of the American Academy of Dermatology.
Free Case Evaluation for Dupixent Drug Injury Lawsuits
We encourage you to submit a Dupixent Cancer Case Evaluation Form online – it is free, confidential, and there is no obligation. Or, if you prefer, call 910-256-2971 to speak directly to attorney Tom Lamb about a possible Dupixent drug injury lawsuit. Either way, you will get Mr. Lamb’s impressions – not an intake person, a paralegal, or some other lawyer – about your case based on his over 20 years of experience handling drug injury cases.
Legal Information About Dupixent Drug Injury Lawsuits
The Dupixent drug injury lawsuits for Dupixent-related cancers would be filed against the pharmaceutical companies Sanofi and Regeneron, the manufacturers of Dupixent, based on the allegation that Sanofi and Regeneron failed to warn patients and doctors about the possible increased risk of T-cell lymphoma, including cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), mycosis fungoides, and Sézary syndrome.
A couple of the legal liability allegations that might be included in Dupixent drug injury lawsuits are:
- Defendants Regeneron and Sanofi knew or should have known of the potential of Dupixent to exacerbate or accelerate pre-existing T-cell lymphoma, including CTCL and PTCL, or increase susceptibility to its development.
- Defendants failed to adequately test Dupixent to investigate the risks, including the potential of exacerbating pre-existing T-cell lymphoma or increasing susceptibility to its development.
Essentially, these Dupixent drug injury lawsuits against Regeneron and Sanofi are based on various allegations having to do with their wrongful conduct concerning the potential increased risks for patients using Dupixent later being diagnosed with Dupixent-related cancers, such as T-cell lymphoma, cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), mycosis fungoides (MF), or Sézary syndrome.
If we can assist you with a possible Dupixent drug injury lawsuit, feel free to submit a Dupixent Cancer Case Evaluation Form online or call 910-256-2971 to discuss your Dupixent-related cancer diagnosis with attorney Tom Lamb.
Most Recent Article About Dupixent-related Cancers
Dupixent Cancer Cases: Legal and Medical Information
Dupixent cancer cases are being filed as product liability lawsuits against the drug companies Sanofi and Regeneron, based on various allegations concerning the Defendants’ failure to warn patients and their doctors about an increased risk of T-cell lymphoma, which appears to be a Dupixent-related side effect.
In summary, these Dupixent cancer cases against Sanofi and Regeneron are based on their wrongful conduct in connection with the development, testing, labeling, packaging, promotion, advertising, marketing, distribution, and selling of Dupixent (dupilumab).
To read more of this article, click below:
Some of the allegations contained in the lawsuits for Dupixent cancer cases are:
- Defendants Regeneron and Sanofi knew or should have known of the potential of Dupixent to exacerbate or accelerate pre-existing T-cell lymphoma, including cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL), or increase susceptibility to its development.
- Defendants failed to adequately test Dupixent to investigate the risks, including the potential of exacerbating pre-existing T-cell lymphoma or increasing susceptibility to its development.
- Defendants failed to warn physicians and patients that Dupixent should not be prescribed or administered to patients with confirmed or suspected T-cell lymphoma, including CTCL and PTCL.
As background, here is some basic medical information relevant to these Dupixent cancer cases:
- There are several types of T-cell lymphoma, including cutaneous T-cell lymphoma (CTCL) and peripheral T-cell lymphoma (PTCL).
- CTCL is a T-cell lymphoma that begins in the skin. Mycosis fungoides and Sézary syndrome are the two most common subtypes of CTCL.
- PTCL refers to systemic T-cell lymphomas that are found in the lymph nodes, other organs, and the blood. Also, some types involve the skin.
- T-cell lymphomas, both CTCL and PTCL, are a subtype of non-Hodgkin lymphoma (NHL).
We are currently investigating possible Dupixent cancer cases for patients who were diagnosed with one of the following medical conditions, some time after they started using Dupixent:
- T-cell lymphoma
- cutaneous T-cell lymphoma (CTCL)
- peripheral T-cell lymphoma (PTCL)
- Mycosis fungoides
- Sézary syndrome
For individuals with a Dupixent-related cancer case, we encourage them to submit a Dupixent Cancer Case Evaluation Form online or call 910-256-2971 to discuss their potential case with attorney Tom Lamb.
[Read the article in full at source]Earlier articles about Dupixent-related Cancers by attorney Tom Lamb on the Side Effects Blog: